Teva to pay $27.6m to settle fraud charges
"The pipeline of innovative drugs is not persuasive enough to fill the vacuum that Copaxone will leave when its patent expires."
The many open questions following the publication of Teva Pharmaceutical Industries Ltd's (NYSE: TEVA; TASE: TEVA) strategic plan have prompted Clal Finance Ltd. to cut its target price for the share from $46 to $40, a premium of just 6% on yesterday's closing price of $37.78 on the New York Stock Exchange, although it reiterated its "Market perform" recommendation.
"In our opinion, Teva's new strategy reflects a change in direction, the results of which will only be clear in the long term," says Clal Finance analyst Jonathan Kreizman. "In the meantime, the pipeline of innovative drugs is not persuasive enough to fill the vacuum that Copaxone will leave when its patent expires and the pending competition." He adds that Teva's return to investors remains high at 20-25%, which leaves the company stuck midway between a growth company and a value company.
Kreizman mentions several factors which will affect Teva's share. The first is whether the company will be able to build substantial innovative activity in such a competitive market. He estimates that Teva's revenue from innovative drugs will fall by 22% by 2017, belying the company's forecast of stable revenue.
Kreizman says that Teva's forecasts include launches of drugs currently undergoing Phase II clinical trials, which he excludes because of their high uncertainty. He believes that Teva's new strategy on innovative drugs is not what the market expected to hear.
Kreizman also questions whether Teva's plan to cut costs by $1.5-2 billion is realistic. "The slides are clear, but implementation in the field is less so," he says, and offers a more conservative reduction of $700 million in 2015.
Kreizman estimates that Teva's multiple sclerosis drug Copaxone, its most widely sold drug, accounts for 56% of the company's profit. He predicts $3.93 billion in sales in 2013, followed by an 18% reduction in 2014.
Teva is optimistic about its double-dosage Copaxone (40mg), which is injected three times a week, instead of a daily injection. Kreizman estimates that Teva has "a fleeting window of opportunity to switch patients to the triweekly dosage, in an attempt to prevent existing patients switching to BG-12 (Biogen Idec Inc.'s (Nasdaq: BIIB) rival treatment for multiple sclerosis S.H.V.)"
Teva recently petitioned the US Food and Drug Administration (FDA) to block marketing approval for BG-12, claiming that it was liable to cause kidney damage. Kreizman doubts that Teva will be able to prevent approval of the drug.
More than a quarter of Kreizman's new target price of $40 for Teva comes from Copaxone - $11.90 per share.
Teva's share price has fallen 4% since the company published its strategic plan in December. Its current market cap is $32.8 billion.
Published by Globes [online], Israel business news - www.globes-online.com - on January 17, 2013
© Copyright of Globes Publisher Itonut (1983) Ltd. 2013
You comment was recieved and soon will be published.
Load more comments
The company does not admit to charges of paying a psychiatrist to prescribe Clozapine.
Dermatology co Foamix mulls Nasdaq IPO
The developer of foam-based dermatology treatments is seeking underwriters.
Can-Fite Biopharma raises $5m
The proceeds will finance clinical trials for psoriasis, glaucoma, and liver cancer treatments.
Teva switching Copaxone users to new dosage
"Bloomberg": Teva has switched 8.7% of Copaxone's multiple sclerosis patients to the 40 milligram dosage.
Immune Pharmaceuticals raises $11.7m on Nasdaq
The money raised will fund a Phase II trial of ulcerative colitis drug bertilmumab.
XTL Biopharma files to raise $40m on Nasdaq
XTL plans to initiate a large Phase IIb clinical trial for the treatment of Lupus.
Teva launches generic cancer drug
Brand Xeloda, made by Genentech, had $754 million in US sales in 2013.
Yelin Lapidot takes stake in Brainsway
Brainsway raised NIS 41 million in the private placement.
Barclays upgrades Teva
Barclays raised its recommendation to "Overweight" and its target price to $65.
BiolineRX raises $24m in Nasdaq offering
Three months ago, the company announced promising preliminary clinical trial results.
Teva VP Ika Abravanel resigns
Abravanel's is the first senior departure from Teva since Erez Vigodman became CEO.
FDA approves Pluristem cell production facility
Pluristem's Haifa plant can produce 150,000 doses of PLX cells annually.
Desheh: Splitting Teva will not create value
Teva CFO Eyal Desheh says Teva's tight integration means that a split makes no sense.
InsuLine expanding in Europe
24Care will distribute the company's InsuPad product in the Netherlands and Belgium.
Teva launches generic breast cancer, osteoporosis drug
Teva has 180 days of marketing exclusivity for generic Evista, which had 2013 US sales of $824 million.
BiolineRX raising $21m in Nasdaq secondary offering
The company will use the proceeds to develop leukemia and celiac disease drugs.
MediWound sets terms for $92m Nasdaq IPO
The burns and wounds treatment developer's offering is at a value of $350-370 million.
Opko losses triple
CEO Phillip Frost: From an R&D perspective, all our programs are progressing.
D-Pharm doubles on good interim stroke study results
The Phase IIa trial interim results found the company's drug was safe for cerebral strokes.
Perrigo selling OTC drugs through Amazon
Perrigo: It is also a platform for obtaining good information about consumer behavior.
Teva launches bipolar, schizophrenia treatment
Adasuve is the first orally inhaled medicine for the acute treatment of agitation in schizophrenia and bipolar I disorder.
Perrigo acquires Aspen Global products for $51m
Perrigo bought value-brand OTC products sold in Australia and New Zealand.
Galmed updates $30m Nasdaq IPO prospectus
The liver disease drug developer will issue shares at a company value of $132 million.
Enzymotec shareholders raise $131m in offer to sell
Kibbutz Ma'anit's Galam reportedly sold shares for $46 million.
Compugen raises $63m, Magic $51m
The two companies held secondary offerings on Nasdaq on the basis of shelf prospectuses.
If Rose Fostanes played basketball
Reforms in regulations for foreign caregivers are welcome, but don't go far enough.
Private treatment kills public healthcare
If the German Committee validates private healthcare, it will be the last nail in public healthcare's coffin, argues Prof Dani Filc.
Reducing the number of polyps that colonoscopies miss
EndoChoice's Israel development center has devised an endoscope with a 330-degree arc.
Neopharm moves into orphan drugs
The company, better known for marketing others' products, has been quietly building up its innovative capacity, as VP Tal Fuhrer relates..
Merck Serono Israel incubator nurtures early stage projects
Merck Germany head of pharmaceuticals Dr. Stefan Oschmann says R&D is enjoying a renaissance at big pharma companies.